Kidney Disease News and Research

RSS

Dialysis patients with kidney failure more likely to develop serious complications from flu

For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.

1 Oct 2011

CorMedix to primarily focus on commercialization of Neutrolin in Europe

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has decided based upon recent developments to primarily focus on the commercialization of Neutrolin in Europe.

1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

UC San Diego professor receives NIDDK grant to study kidney complications related to diabetes

Kumar Sharma, MD, FAHA, professor of medicine at the University of California, San Diego School of Medicine and director of the Center for Renal Translational Medicine, has received a $5.9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to study kidney complications related to type 1 and type 2 diabetes.

1 Oct 2011

FDA CDER assigned for pre-market review of CorMedix's Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration advised CorMedix, that the Center for Drug Evaluation and Research has been assigned as the lead agency for the pre-market review of Neutrolin.

29 Sep 2011

People with prehypertension have higher risk of experiencing future stroke

People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.

29 Sep 2011

ECDA welcomes UN High Level Meeting on Non Communicable Diseases

The European Chronic Disease Alliance (ECDA) welcomes the UN High Level Meeting on Non Communicable Diseases (NCDs) to address the world biggest killers. "It is a memorable day in the history of public health. Discussing non communicable diseases at the UN table gives a strong sense of the burden it represents to human kind and the recognition that NCDs is a challenge for all nations in the world", declared Professor Michel Komajda, President of the European Society of Cardiology, an active member of the ECDA.

26 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Long-term immunosuppressants improve survival for lupus patients with ESKD

Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease—a finding that could reverse long-standing clinical practice.

21 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Patients with chronic kidney disease do not need to undergo painful invasive procedures

Equations that estimate a patient's kidney function work as well as direct, invasive measurements, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

16 Sep 2011

Demand for kidney transplant and dialysis increases due to diabetes prevalence

A survey reveals that the need for kidney transplants and dialysis is expected to soar by 2020 mainly due to a rise in diabetics developing chronic kidney disease and needing treatment. The total number of Australians being treated for end-stage kidney disease is forecast to rise by up to 80 per cent to about 4300 in the coming decade. While the fact that Australia's population is ageing and growing means more people are likely to develop end-stage kidney disease, the number of diabetics with the condition is also on the rise.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Sickle cell trait does not increase risk of severe kidney disease in African-Americans

Researchers at Wake Forest Baptist Medical Center report that sickle cell trait is not a risk factor for the development of severe kidney disease in African-Americans.

15 Sep 2011

Diabetes epidemic grips the world

Experts are horrified with the rise of numbers of diabetics worldwide. A staggering 366 million people around the world have either Type 1 or 2 diabetes, says the International Diabetes Federation. The disease has taken a deadly toll, causing 4.6 million deaths each year, or one death every seven seconds. The number of sufferers was pegged at 285 million worldwide in 2009. Since then, China reported 92.4 million people with the condition, more than double the federation’s estimate. The diabetes epidemic is also heavy on healthcare spending, to the tune of $465 billion a year to fight the disease.

14 Sep 2011

African-Americans have higher risk of high blood pressure earlier

...

13 Sep 2011

Blood levels of FGF-23 can help predict CKD patients at risk of heart problems

The blood levels of a particular hormone can help predict which kidney disease patients will develop heart problems, need dialysis, and die prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

9 Sep 2011

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

The American Physiological Society is sponsoring the 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels, being held September 18-22 at the Asilomar Conference Grounds in Pacific Grove, Calif. This scientific conference explores the connection between fluid balance in the body and hypertension, a growing global health concern.

8 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011